Sector News

Small molecule chief named head of gRED in rejig at the top of Genentech

December 15, 2014
Life sciences
There has been a change at the top of gRED. Having shepherded Genentech’s R&D operations through the takeover by Roche, Richard Scheller will retire at the end of 2014. Roche has lined up Michael Varney, Genentech’s head of small molecule drug discovery, to replace Scheller.
 
The rejig marks the first change at the top of Genentech Research and Early Development (gRED) since the early days of the Roche takeover, when the Swiss pharma fenced off the biotech’s early-stage R&D from its own operations. Scheller–who was Genentech’s chief scientific officer prior to the acquisition–was put in charge of the standalone R&D unit within one month of Roche closing the deal.
 
Under Scheller, gRED has propped up its parent company by delivering a string of cancer drugs–offset by the occasional failure such as MetMab–and developed promising candidates for diseases including age-related macular degeneration. Genentech even made a rare big-ticket deal, paying $725 million in cash–and agreeing to up to $1 billion in milestones–to takeover Seragon Pharmaceuticals and its breast cancer program.
 
The challenge of realizing the promise of Seragon’s science will now fall on Varney, who will take over as head of gRED in January. Varney is stepping up from his current position as head of small molecule drug discovery, a role he took in 2005. Back then, Genentech was just setting up its small molecule R&D operation. Now, it has named a man who has spent his career working on small molecules–first at Viracept developer Agouron Pharmaceuticals–as the head of its early-stage R&D operation.
 
By Nick Paul Taylor
 

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach